Skip to main content

Jhunjhunwala among proposed investors for VA Tech Wabag's Rs 120-crore Preferential Issue

 Rekha Rakesh Jhunjhunwala will likely be issued up to 50 lakh shares for Rs 80 crore, Basera Home Finance Private Limited will pick up 15 lakh at Rs 24 crore and Sushma Anand Jain & Anand Jai will get 10 lakh shares at Rs 16 crore.

VA Tech Wabag is planning to raise Rs 120 crore from three marquee investors, including Rekha Jhunjhunwala (wife of ace investor Rakesh Jhunjhunwala).

In an exchange filing, the Chennai-based water and sewage treatment company said its board had considered equity infusion on a preferential basis at Rs 160 apiece, which is at 30 percent discount to the stock’s closing price on August 25.

Rekha Rakesh Jhunjhunwala will be issued up to 50 lakh shares for Rs 80 crore, Basera Home Finance Private Limited will pick up 15 lakh at Rs 24 crore and Sushma Anand Jain and Anand Jai will get 10 lakh shares at Rs 16 crore.

"This is the first time the company has proposed to raise equity capital since its IPO in 2010 and we believe that this well-timed equity infusion will provide the necessary growth capital for the company to scale greater heights. We look forward to a long-term association with each of the potential incoming investors," MD & Group CEO Rajiv Mittal said.

With its technology focus, asset-light model and global presence, the company is well-positioned to consolidate its leadership in the water technology sector, he said.

In the backdrop of growing awareness and need for sustainable businesses, across the world, the company is an ideal destination for global investors, especially for ESG focused investors, Mittal said.

Despite the approval of equity infusion plans, shares of VA Tech Wabag were trading at Rs 223, down 1.89 percent on the BSE.

The stock touched an intraday high of Rs 235 and an intraday low of Rs 210.10. On a year-to-date basis, it is up nearly 22 percent.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...